RT Journal Article
SR Electronic
T1 Clinical Outcome of Neurological patients with COVID-19: the impact of Healthcare organization improvement between waves
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.11.19.21266606
DO 10.1101/2021.11.19.21266606
A1 Cristillo, Viviana
A1 Pilotto, Andrea
A1 Benussi, Alberto
A1 Libri, Ilenia
A1 Giunta, Marcello
A1 Morotti, Andrea
A1 Gipponi, Stefano
A1 Locatelli, Martina
A1 Piccinelli, Stefano Cotti
A1 Mazzoleni, Valentina
A1 Schiano di Cola, Francesca
A1 Masciocchi, Stefano
A1 Pezzini, Debora
A1 Scalvini, Andrea
A1 Premi, Enrico
A1 Cottini, Elisabetta
A1 Gamba, Massimo
A1 Magoni, Mauro
A1 Fontanella, Marco Maria
A1 Padovani, Alessandro
YR 2021
UL http://medrxiv.org/content/early/2021/11/21/2021.11.19.21266606.abstract
AB Objective The aim of this study is to evaluate the differences of clinical presentations and the impact of healthcare organization on outcomes of neurological COVID-19 patients admitted during the first and second pandemic waves.Methods In this single center cohort study, we included all patients with SARS-CoV-2 infection admitted to a Neuro-COVID Unit. Demographic, clinical and laboratory data were compared between patients admitted during the first and second waves of COVID-19 pandemic.Results 223 patients were included, of whom 112 and 111 hospitalized during the first and second pandemic waves, respectively. Patients admitted during the second wave were younger and exhibited pulmonary COVID-19 severity, resulting in less oxygen support (n=41, 36.9% vs n=79, 70.5%, p<0.001) and lower mortality rates (14.4% vs 31.3%, p=0.004). The different healthcare strategies and early steroid treatment emerged as significant predictors of mortality independently from age, premorbid conditions and COVID-19 severity in cox regression analyses.Conclusions Differences in healthcare strategies during the second phase of COVID-19 pandemic probably explain the differences in clinical outcomes independently of disease severity, underlying the importance of standardized early management of neurological patients with SARS-CoV-2 infection.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study did not receive any fundingAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of University of Brescia gave ethical approval for this workI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present work are contained in the manuscript